More tools:Markets·Screener·Research·Chat

ADC Therapeutics SA (ADCT) Financial Statements

ADC Therapeutics SA
SIC 2834 · PHARMACEUTICAL PREPARATIONS
FIGI BBG00Q6Q3RN0
XNYS · usd
1.30▼ 0.06 (-4.41%)
As of 2026-09-08
Valuation
Market Cap
Enterprise Value
Trailing P/E—
Price / Sales
EV / Revenue
EV / EBITDA
Financial Highlights
Revenue (TTM)
Net Income (TTM)
EBITDA
Diluted EPS (TTM)
EBITDA Margin
Net Debt
Trading Information
Previous Close1.36
Day's Range1.27 – 1.35
52-Week Range0.78 – 4.98
Volume929.0K
Avg Volume1.5M
Share Statistics
Shares Outstanding
Employees193
ExchangeXNYS
Listed2020-05-15
Share count as of August 3, 2026
Loading Income Statement…
Key questions about ADC Therapeutics SA (ADCT)
What is ADC Therapeutics SA's Market Cap?
ADC Therapeutics SA's Market Cap is $166.0M, based on as-reported figures from SEC (XBRL) filings.
What is ADC Therapeutics SA's Enterprise Value?
ADC Therapeutics SA's Enterprise Value is $63.5M, based on as-reported figures from SEC (XBRL) filings.
What is ADC Therapeutics SA's Price / Sales?
ADC Therapeutics SA's Price / Sales is 2.1×, based on as-reported figures from SEC (XBRL) filings.
What is ADC Therapeutics SA's EV / Revenue?
ADC Therapeutics SA's EV / Revenue is 0.8×, based on as-reported figures from SEC (XBRL) filings.
What is ADC Therapeutics SA's EV / EBITDA?
ADC Therapeutics SA's EV / EBITDA is n/m, based on as-reported figures from SEC (XBRL) filings.
What is ADC Therapeutics SA's Revenue (TTM)?
ADC Therapeutics SA's Revenue (TTM) is $79.6M, based on as-reported figures from SEC (XBRL) filings.
What is ADC Therapeutics SA's Net Income (TTM)?
ADC Therapeutics SA's Net Income (TTM) is -$96.9M, based on as-reported figures from SEC (XBRL) filings.
What is ADC Therapeutics SA's EBITDA?
ADC Therapeutics SA's EBITDA is -$98.8M, based on as-reported figures from SEC (XBRL) filings.
What is ADC Therapeutics SA's Diluted EPS (TTM)?
ADC Therapeutics SA's Diluted EPS (TTM) is -0.76, based on as-reported figures from SEC (XBRL) filings.
What is ADC Therapeutics SA's EBITDA Margin?
ADC Therapeutics SA's EBITDA Margin is -124.2%, based on as-reported figures from SEC (XBRL) filings.
Showing the most recent year. Subscribe for full statement history.
Income Statement(in thousands of USD, except per-share data)
Source: Akyla.ai
Line ItemJun 30, 2026Mar 31, 2026Dec 31, 2025Sep 30, 2025Jun 30, 2025Mar 31, 2025Dec 31, 2024Sep 30, 2024Jun 30, 2024Mar 31, 2024Dec 31, 2023Sep 30, 2023Jun 30, 2023Mar 31, 2023
Revenue
Product revenues, net—
License revenues and royalties—
Total revenue, net
YoY growth+2.2%-9.5%+36.4%-11.0%
Operating expense
Cost of product sales
Research and development
Selling and marketing
General and administrative
Restructuring and impairment expenses—
Total operating expense
% of revenue-232.0%-221.1%-177.7%-288.5%
Loss from operations
% of revenue-132.0%-121.1%-77.7%-188.5%
Other income (expense)
Interest income
Interest expense
Other, net
Total other income (expense), net
Loss before income taxes
Income tax expense
Net loss
% of revenue-86.1%-158.1%-27.8%-249.4%
Net loss per share, basic (in dollars per share)
Net loss per share, diluted (in dollars per share)